Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Investors: Take Advantage of Double Fed Tax Credits on Critical Minerals Project (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Neogenomics Inc NEO

Healthcare
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories. The Company operates through two segments: Clinical Services, and Advanced Diagnostics. The Clinical Services segment provides various clinical-testing services related to oncology diagnostics, community-based oncology and pathology sales, patient engagement, and clinical decision support. The Clinical Services segment also offers Trapelo, a decision-making informatics tool, to help health care professionals navigate the rapidly evolving field of precision medicine. The Advanced Diagnostics segment includes pharma services, informatics, research and development, and minimal residual disease, liquid biopsy and therapy selection business development. Additional offerings within the Advanced Diagnostics portfolio include Informatics, which involves the licensing of de-identified data to pharmaceutical and biotech customers in the form of either retrospective records or prospective deliveries of data.


NDAQ:NEO - Post by User

Neogenomics Inc
Bullboard Posts
Next >>
User Avatar Image
(4)
•••
  • zeropointenergyX
Post by zeropointenergyon Mar 19, 2021 2:37am
159 Views
Post# 32835815

spending US$4.5bn to expand capacity at plants in the Chines

spending US$4.5bn to expand capacity at plants in the Chines

Chinese new-vehicle sales on road to recovery in 2021 ...

www.eiu.com › Home › The EIU Update
Feb. 23, 2021 — China's total new-vehicle market rebounded sharply in the last eight months of 2020. ... Chinese CV sales, comprising trucks and buses, recorded the ... to spending US$4.5bn to expand capacity at plants in the Chinese ..Great share!
Bullboard Posts
Next >>